Published August 6, 2010 | Version v1
Journal article

SLUG/SNAI2 and Tumor Necrosis Factor Generate Breast Cells With CD44+/CD24- Phenotype

  • 1. Department of Surgery, Indiana University School of Medicine, West Walnut Street, Indianapolis, IN 46202 (United States)
  • 2. Department of Medicine, Indiana University School of Medicine, West Walnut Street, Indianapolis, IN 46202 (United States)
  • 3. Department of Biochemistry and Molecular Biology, Barnhill Drive, Indiana University School of Medicine, Indianapolis, IN 46202 (United States)
  • 4. Department of Pathology, Indiana University School of Medicine, Barnhill Drive, Indianapolis, IN 46202 (United States)

Description

Breast cancer cells with CD44+/CD24- cell surface marker expression profile are proposed as cancer stem cells (CSCs). Normal breast epithelial cells that are CD44+/CD24- express higher levels of stem/progenitor cell associated genes. We, amongst others, have shown that cancer cells that have undergone epithelial to mesenchymal transition (EMT) display the CD44+/CD24- phenotype. However, whether all genes that induce EMT confer the CD44+/CD24- phenotype is unknown. We hypothesized that only a subset of genes associated with EMT generates CD44+/CD24- cells. MCF-10A breast epithelial cells, a subpopulation of which spontaneously acquire the CD44+/CD24- phenotype, were used to identify genes that are differentially expressed in CD44+/CD24- and CD44-/CD24+ cells. Ingenuity pathway analysis was performed to identify signaling networks that linked differentially expressed genes. Two EMT-associated genes elevated in CD44+/CD24- cells, SLUG and Gli-2, were overexpressed in the CD44-/CD24+ subpopulation of MCF-10A cells and MCF-7 cells, which are CD44-/CD24+. Flow cytometry and mammosphere assays were used to assess cell surface markers and stem cell-like properties, respectively. Two thousand thirty five genes were differentially expressed (p < 0.001, fold change ≥ 2) between the CD44+/CD24- and CD44-/CD24+ subpopulations of MCF-10A. Thirty-two EMT-associated genes including SLUG, Gli-2, ZEB-1, and ZEB-2 were expressed at higher levels in CD44+/CD24- cells. These EMT-associated genes participate in signaling networks comprising TGFβ, NF-κB, and human chorionic gonadotropin. Treatment with tumor necrosis factor (TNF), which induces NF-κB and represses E-cadherin, or overexpression of SLUG in CD44-/CD24+ MCF-10A cells, gave rise to a subpopulation of CD44+/CD24- cells. Overexpression of constitutively active p65 subunit of NF-κB in MCF-10A resulted in a dramatic shift to the CD44+/CD24+ phenotype. SLUG overexpression in MCF-7 cells generated CD44+/CD24+ cells with enhanced mammosphere forming ability. In contrast, Gli-2 failed to alter CD44 and CD24 expression. EMT-mediated generation of CD44+/CD24- or CD44+/CD24+ cells depends on the genes that induce or are associated with EMT. Our studies reveal a role for TNF in altering the phenotype of breast CSC. Additionally, the CD44+/CD24+ phenotype, in the context of SLUG overexpression, can be associated with breast CSC 'stemness' behavior based on mammosphere forming ability

Availability note (English)

Available from http://dx.doi.org/10.1186/1471-2407-10-411; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087321

Additional details

Publishing Information

Journal Title
BMC cancer (Online)
Journal Volume
10
Journal Page Range
p. 411
ISSN
1471-2407

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
46098892
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
GENES; HCG; MAMMARY GLANDS; NEOPLASMS; PHENOTYPE; RISE; STEM CELLS; SURFACES
Descriptors DEC
ANIMAL CELLS; BODY; DISEASES; GLANDS; GONADOTROPINS; HORMONES; MODIFIED IN-SITU PROCESSES; ORGANIC COMPOUNDS; ORGANS; PEPTIDE HORMONES; PITUITARY HORMONES; PROTEINS; SOMATIC CELLS

Optional Information

Copyright
Copyright (c)2010 Bhat-Nakshatri et al
Notes
PMCID: PMC3087321; PUBLISHER-ID: 1471-2407-10-411; PMID: 20691079; OAI: oai:pubmedcentral.nih.gov:3087321; licensee BioMed Central Ltd.